SIBP-03 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIBP-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIBP-03 is under development for the treatment of advanced malignant solid tumors including recurrent head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC) and breast cancer with high HER2 expression. The drug candidate is a recombinant monoclonal antibody administered through intravenous route. It acts by targeting tyrosine kinase type cell surface receptor (HER3).
Shanghai Institute of Biological Products overview
Shanghai Institute of Biological Products (SIBP) engaged in production and distribution of bacterial and virus vaccines, toxoids, and analogous products. It serves various markets including medical clinics and hospitals, pharmaceuticals, health information systems, dental and orthodontic practitioners. The company is headquartered in Shanghai, China.
For a complete picture of SIBP-03’s drug-specific PTSR and LoA scores, buy the report here.